British Viral Hepatitis Group
The BVHG aims to improve the management and study of patients with chronic viral liver disease. The group brings together UK hepatologists, gastroenterologists, infectious disease physicians, nurses and allied professionals as well as virologists, epidemiologists and scientists with an interest in viral diseases of the liver.
The work of the BVHG
The BVHG organises 2/3 day meetings each year on varied topics related to viral hepatitis, as well as co-organising other sessions and meetings. These have proven to be very successful and well attended.
There is a Maternity and Paediatrics sub-group as well as a soon to be formed Pharmacists sub-group affiliated to the BVHG.
The BVHG is also involved in reporting and representing to NICE and other organisations/government bodies on issues related to viral hepatitis, and has developed an advocacy role for clinicians and others interested in viral hepatitis care, treatment and study.
The BVHG is involved in liaising with the British Society of Gastroenterology Liver Section as well as the British HIV Association in areas of mutual interest. It played a pivotal role in the review of the best available evidence in the Management of Hepatitis C during a Consensus Conference in 2015.
It plans to develop more online educational content including setting up a Post-Conference Feedback Web Session.
The BVHG Committee
|BVHG Chair||Dr Ahmed Elsharkawy, University Hospitals Birmingham|
|BVHG Secretary||Dr Will Gelson, Cambridge University Hospitals|
Dr Ahmed Elsharkawy, Consultant Hepatologist, University Hospitals Birmingham
Consultant Hepatologist at the Queen Elizabeth Hospital since March 2012. His main clinical interests are Viral Hepatitis, Nutrition in Liver Disease, Acute Liver Failure, liver disease in pregnancy; drug induced liver injury and live related liver transplantation. He is principal investigator on a number of trials of acute on chronic liver failure and co-investigator on a number of phase 2 and phase 3 trials in the field of viral hepatitis. He has a major interest in the management of viral hepatitis outside traditional settings and is setting up Outreach and In-reach clinics in his locality.
Dr Will Gelson, Consultant Hepatologist, Addenbrooke’s Hospital, Cambridge
Dr Gelson is also the lead of the Eastern Hepatitis Network setting up the hepatitis C Eastern Hepatitis ODN and is the viral hepatitis lead for Cambridge University Hospitals. He has networked on a national scale in relation to viral hepatitis. His main interests are viral hepatitis and liver transplantation.
UK Position Statement on the use of Organs from Hepatitis C Viraemic Donors in Hepatitis C Negative Recipients:
Hepatitis C in the UK 2018 report - a copy of the report, press release, infographic and slide set can be found at the following link: https://www.gov.uk/government/news/deaths-from-hepatitis-c-have-fallen-by-11-per-cent-in-the-last-year .
Business Case Template - Hepatitis C Test & Treat Nurse-Led Community Based Service. Download the template below:
|This business case template is based on data from a pilot study undertaken in Brighton. Therefore acknowledgements to Dr Sumita Verma, Reader in Medicine Brighton and Sussex Medical School and Hon Consultant Hepatology, Brighton and Sussex University Hospital, Specialist Hepatitis Nurse Margaret O'Sullivan, Brighton and Sussex University Hospital and to all other staff at Brighton services (acute trust, substance misuse & public health) who have supported this important HCV development. Thank you to Alison McKinlay, Service Manager Brighton and Sussex University Hospital, for sharing the BSUH business case and local financial data. The template has been funded and commissioned by Gilead Sciences Ltd. Gilead had no editorial control over the document.|
The first BVHG and BASL Best Practice for ODN Stakeholders Meeting which was held on the 10–11 January 2018 in Manchester. The summary of the outputs from the meeting is provided in form of a meeting report; Download BVHG-BASL ODN meeting report Jan 2018.pdf
The report highlights the limitations of the current HCV treatment model, and provides suggestions on how it can be modified and improved. The report describes best practice examples for eliminating HCV for ODNs to take and adapt to work in their area. The intention is that this information will provide all ODNs with a framework to develop the 5-year plans needed to meet their CQUIN requirement, and importantly to also leave them well placed to deliver on the World Health Organisations goal of HCV elimination by 2030.
Supplementary BVHG and BASL Best Practice for ODN Stakeholders Meeting Information:
Read the Hepatitis C Coalition Report on the Operational Delivery Networks – December 2017 > here.
Read the Hepatitis C Coalition Report - Signposting the way to elimination by 2025 - July 2018 > here Download Hepatitis C Coalition Signposting Elimination July 18.pdf.
The British Hepatology Pharmacy Group (BHPG) are currently working with a number of national bodies to facilitate community pharmacies testing and treating Hepatitis C patients in England. Due to the complexities around contracting and pricing, we are looking at bespoke pathways to enable this. More details will be posted in due course. For further information contact Adele Torkington Adele.Torkington@pat.nhs.uk or Tina Shah email@example.com .